Immune Design (IMDZ) Tops Q3 EPS by 2c

Immune Design (NASDAQ: IMDZ) reported Q3 EPS of ($0.37), $0.02 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $4.7 million versus the consensus estimate of $4.1 million.

For earnings history and earnings-related data on Immune Design (IMDZ) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance